Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Current Assets (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Current Assets data on record, last reported at $172.2 million in Q1 2026.

  • On a quarterly basis, Current Assets rose 82.85% to $172.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $172.2 million, a 82.85% increase, with the full-year FY2025 number at $180.1 million, up 82.94% from a year prior.
  • Current Assets reached $172.2 million in Q1 2026 per IKT's latest filing, down from $180.1 million in the prior quarter.
  • Over the last five years, Current Assets for IKT hit a ceiling of $180.1 million in Q4 2025 and a floor of $4.2 million in Q3 2024.
  • A 5-year average of $56.5 million and a median of $27.8 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: tumbled 76.13% in 2024, then surged 1774.34% in 2025.
  • Tracing IKT's Current Assets over 5 years: stood at $24.4 million in 2022, then plummeted by 41.69% to $14.2 million in 2023, then surged by 592.78% to $98.5 million in 2024, then soared by 82.94% to $180.1 million in 2025, then decreased by 4.4% to $172.2 million in 2026.
  • Business Quant data shows Current Assets for IKT at $172.2 million in Q1 2026, $180.1 million in Q4 2025, and $78.5 million in Q3 2025.